Advertisement
Advertisement
U.S. Markets open in 1 hr 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0265+0.0040 (+17.78%)
At close: 02:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0225
Open0.0221
BidN/A x N/A
AskN/A x N/A
Day's Range0.0190 - 0.0270
52 Week Range0.0016 - 0.0800
Volume1,571,174
Avg. Volume461,407
Market Cap14.254M
Beta (5Y Monthly)300.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study

    Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Paul Michaels, Chairman and President of Curative Biotechnology, said,

  • GlobeNewswire

    Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

    Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the Company’s proposed 1-for-400 reverse stock split. In addition, the Company expects to grant the underwriter a 45-day option to pu

  • GlobeNewswire

    Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

    Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc. (https://biotheryx.com

Advertisement
Advertisement